<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        15-887-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SEPTRIN 240MG SUSP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SULFAMETHOXAZOLE, TRIMETHOPRIM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40, 8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        16.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ASPEN" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ASPEN
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASPEN PHARMA TRADING LIMITED (APTL)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01EE01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1. What Septrin Paediatric Suspension is and what it is used for</strong></p><p>Septrin Paediatric 40 mg/200 mg per 5 ml Oral Suspension (called &lsquo;Septrin Paediatric Suspension&rsquo; in this leaflet) is a combination of two different antibiotics called sulfamethoxazole and trimethoprim, which is used to treat infections caused by bacteria. This medicine combination is also named as co-trimoxazole. Like all antibiotics, Septrin Paediatric Suspension only works against some types of bacteria. This means that it is only suitable for treating some types of infections.</p><p>Septrin Paediatric Suspension can be used to treat or prevent:</p><ul><li>&nbsp;lung infections (pneumonia) caused by the micro-organism, Pneumocystis jirovecii (previously known as Pneumocystis carinii ) (some people call this &lsquo;PJP&rsquo;).</li></ul><p>Septrin Paediatric Suspension can be used to treat:</p><ul><li>&nbsp;urinary bladder or urinary tract infections (water infections).</li><li>&nbsp;respiratory tract infections such as bronchitis.</li><li>&nbsp;ear infections such as otitis media.</li><li>&nbsp;an infection called nocardiosis which can affect the lungs, skin and brain.</li><li>an infection caused by a bacteria called toxoplasma (toxoplasmosis).</li><li>&nbsp;an infection called brucellosis, if other treatments were not effective and in combination with other agents in line with national treatment guidelines.</li></ul><p>Consideration should be given of official guidance on the appropriate use of antibacterial agents.</p><p>Septrin Paediatric Suspension is indicated in children aged 12 years and under (infants (&gt;6 weeks to &lt;2 years old) and children (&gt;2 to &lt;12 years old).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2. What you need to know before your child takes Septrin</strong> Paediatric Suspension</p><p><strong>Your child should not take Septrin</strong> Paediatric Suspension<strong> if:</strong></p><ul><li>&nbsp;they are allergic to the active substance(s) sulfamethoxazole, trimethoprim, co-trimoxazole or any of the other ingredients of this medicine (listed in section 6).</li><li>&bull; they are allergic to sulphonamide medicines. Examples include sulphonylureas (such as gliclazide and glibenclamide) or thiazide diuretics (such as bendroflumethiazide&ndash;a water tablet).</li><li>&nbsp;they have severe liver or severe kidney problems.</li><li>&nbsp;they have ever had a problem with their blood causing bruises or bleeding (thrombocytopenia).</li><li>&nbsp;you have been told that your child have a rare blood problem called porphyria, which can affect their skin or nervous system.</li><li>&nbsp;Septrin Paediatric Suspension should not be given to infants during the first 6 weeks of life</li></ul><p>If you are not sure if any of the above apply to your child, talk to their doctor or pharmacist before they take Septrin Paediatric Suspension.</p><p><strong>Warnings and precautions</strong><br />Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms (DRESS)) have been reported with the use of Septrin Paediatric Suspension appearing initially as reddish target-like spots or circular patches often with central blisters on the trunk. Additional signs to look for include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). These potentially life-threatening skin rashes are often accompanied by flu-like symptoms including fever. The rash may progress to widespread blistering or peeling of the skin. The highest risk for occurrence of serious skin reactions is within the first weeks of treatment, but it could take up to 8 weeks after drug administration to develop in cases of DRESS (see section 4).</p><p>If your child has developed Stevens-Johnson syndrome, toxic epidermal necrolysis or drug reaction with eosinophilia and systemic symptoms with the use of Septrin Paediatric Suspension your child must not be re-started on Septrin Paediatric Suspension at any time. If your child develops a rash or these skin symptoms, stop giving Septrin Paediatric Suspension, seek urgent advice from a doctor and tell him that your child is taking this medicine.</p><p>Talk to your child&rsquo;s doctor or pharmacist before taking Septrin Paediatric Suspension if:</p><ul><li>&nbsp;They have severe allergies or bronchial asthma.</li><li>&nbsp;You have been told that your child is at risk for a rare blood disorder called porphyria.</li><li>&nbsp;They don&rsquo;t have enough folic acid (a vitamin) in their body - which can make their skin pale and make them feel tired, weak and breathless. This is known as anaemia.</li><li>&nbsp;They have a disease called glucose-6-phosphate dehydrogenase deficiency, which can cause jaundice or spontaneous destruction of red blood cells.</li><li>They have a problem with their metabolism called phenylketonuria and are not on a special diet to help their condition.</li><li>&nbsp;They are underweight or malnourished.</li><li>&nbsp;You have been told by your child&rsquo;s doctor that your child has a lot of potassium in their blood or if your child takes medicines that can increase the amount of potassium in your child&rsquo;s blood, such as diuretics (water tablets, which help increase the amount of urine you produce) steroids (like prednisolone) and digoxin. High levels of potassium in your child&rsquo;s blood, can cause abnormal heart beats (palpitations), nausea, dizziness or headache.</li><li>You have been told by your child&rsquo;s doctor that your child has an abnormally low level of sodium in their blood.</li><li>&nbsp;You have been told by your child&rsquo;s doctor that your child has any serious disorders of the blood and blood forming tissues (haematological disorders). E.g. low blood cell counts.</li><li>&nbsp;They have a kidney disease.</li></ul><p><strong>Other medicines and Septrin Paediatric Suspension</strong></p><p>Tell your child&rsquo;s doctor or pharmacist if your child is taking, has recently taken or might take any other medicines. This is because Septrin Paediatric Suspension can affect the way some medicines work. Also some other medicines can affect the way Septrin Paediatric Suspension works.<br />In particular tell your child&rsquo;s doctor of pharmacist if your child is taking any of the following medicines:</p><ul><li>&nbsp;Diuretics (water tablets), which help increase the amount of urine produced.</li><li>&nbsp;Pyrimethamine, used to treat and prevent malaria, and to treat diarrhoea.</li><li>Ciclosporin, used after organ transplant surgeries.</li><li>&nbsp;Blood thinners such as warfarin.</li><li>&nbsp;Phenytoin, used to treat epilepsy (fits).</li><li>&nbsp;Medicines used to treat diabetes, such as glibenclamide, glipizide or tolbutamide (sulphonylureas) and repaglinide.</li><li>&nbsp;Medicines to treat problems with the way the heart beats such as digoxin or procainamide.</li><li>Amantadine, used to treat Parkinson&rsquo;s disease, multiple sclerosis, flu or shingles.</li><li>Medicines to treat HIV (Human Immunodeficiency Virus), called zidovudine or lamivudine.</li></ul><p>Medicines that can increase the amount of potassium in the blood, such as diuretics (water tablets, which help increase the amount of urine produced such as spironolactone), steroids (like prednisolone) and digoxin.</p><ul><li>&nbsp;Azathioprine, may be used in patients following organ transplant or to treat immune system disorders or inflammatory bowel disease</li><li>&nbsp;Methotrexate, a medicine used to treat certain cancers or certain diseases affecting the immune system.</li><li>&nbsp;Rifampicin, an antibiotic.</li><li>&nbsp;Folinic acid.</li><li>&nbsp;Contraceptive medicines.</li></ul><p><strong>Septrin Paediatric Suspension with food and drink</strong><br />Your child should take Septrin Paediatric Suspension with some food or drink. This will stop them feeling sick (nausea) or having diarrhoea. Although it is better to take it with food, they can still take it on an empty stomach.<br />Make sure your child drink plenty of fluid such as water while they are taking Septrin Paediatric Suspension.</p><p><u><strong>Septrin Paediatric Oral Suspension contains the following excipients with known effects:</strong></u></p><ul><li>&nbsp;6.5 g of 70% Sorbitol solution (non-crystallising) in 10 ml suspension, which is equivalent to 4.55 g of sorbitol per 10 ml. Sorbitol is a source of fructose. If your doctor has told you that you (or your child) have an intolerance to some sugars or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before you (or your child) take or receive this medicine. Sorbitol may cause gastrointestinal discomfort and mild laxative effect.</li><li>Calorific value 2.6 kcal/g sorbitol.</li><li>&nbsp;10 mg of sodium benzoate (E 211) in each 10ml dose which is equivalent to 0.75 mg of sodium benzoate per kg per body weight</li><li>&nbsp;Small amounts of ethanol (alcohol), less than 100 mg per 5 ml spoonful (less than 100mg per 10ml dose).</li><li>&nbsp;Methyl p-hydroxybenzoate (E 218), which may cause allergic reactions (possibly delayed).</li><li>&nbsp;10 mg of sodium benzoate (E 211) in each 10 mL doses</li><li>&nbsp;1mg/1mL., which may increase the risk of jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).</li><li>&nbsp;Less than 1 mmol sodium (23 mg) per 10 ml dose,that is to say essentially &lsquo;sodium free&rsquo;.</li><li>&nbsp;The vanilla flavour contains sulphur dioxide (E220) which may rarely cause severe hypersensitivity reactions and bronchospasm.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3. How to give Septrin paediatric suspension</strong><br />Always ensure your child takes Septrin Paediatric Suspension exactly as their doctor or pharmacist has told you. Check with their doctor or pharmacist if you are not sure.</p><p><strong>Standard Dose</strong><br />Standard dosage recommendations for acute infections<br />Children aged 12 years and under (infants (&gt;6 weeks to &lt;2 years old) and children (&gt;2 to &lt;12 years old):<br />The schedules for children are according to the child&rsquo;s age and body weight provided in the table below:</p><table border="1" cellspacing="0" cellpadding="0" style="width:1023px"><tbody><tr><td colspan="2" style="vertical-align:top; width:1020px"><p>STANDARD DOSAGE</p></td></tr><tr><td style="vertical-align:top"><p><strong>Age</strong></p></td><td style="vertical-align:top; width:760px"><p><strong>Paediatric Suspension</strong></p></td></tr><tr><td style="vertical-align:top"><p>6 to 12 years</p></td><td style="vertical-align:top; width:760px"><p>two 5 ml spoonfuls in a morning and two 5 ml spoonfuls in an evening</p></td></tr><tr><td style="vertical-align:top"><p>6 months to 5 years</p></td><td style="vertical-align:top; width:760px"><p>one 5 ml spoonful in a morning and one 5 ml spoonful in an evening</p></td></tr><tr><td style="vertical-align:top"><p>6 weeks to 5 months</p></td><td style="vertical-align:top; width:760px"><p>one 2.5 ml spoonful in a morning and one 2.5 ml spoonful in an evening</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:760px"><p>The dosage for children is equivalent to approximately 6 mg trimethoprim and 30 mg sulfamethoxazole per kg body weight per day.</p><p>&nbsp;</p></td></tr></tbody></table><ul><li>&nbsp;Septrin Paediatric Suspension should be taken for at least five days</li><li>&nbsp;Make sure that your child finishes the course of Septrin Paediatric Suspension which their doctor has prescribed.</li></ul><p><strong>Special dose</strong><br />The dose of Septrin Paediatric Suspension and how long your child needs to take it depends on the infection they have and how bad it is. Your child&rsquo;s doctor may prescribe you a different dose or length of course of Septrin Paediatric Suspension to</p><ul><li>&nbsp;Treat urinary tract (water) infections.</li><li>&nbsp;Treat and prevent lung infections caused by the bacteria pneumocystis jirovecii (PJP).</li><li>&nbsp;Treat infections caused by the bacteria toxoplasma (toxoplasmosis) or nocardia (nocardiosis) or brucella (brucellosis).</li></ul><p><strong>If your child has kidney problems their doctor may:</strong></p><ul><li>Prescribe a lower dose of Septrin Paediatric Suspension.</li><li>&nbsp;Take blood to test whether the medicine is working properly.</li></ul><p><strong>If your child takes Septrin Paediatric Suspension for a long time their doctor may</strong></p><ul><li>Take blood to test whether the medicine is working properly.</li><li>&nbsp;Prescribe folic acid (a vitamin) for your child to take at the same time as Septrin Paediatric Suspension.</li></ul><p><strong>If your child takes more Septrin Paediatric Suspension than they should</strong><br />If your child takes more Septrin Paediatric Suspension than they should, talk to their doctor or go to a hospital straight away. Take the medicine pack with you.<br />If your child has taken too much Septrin Paediatric Suspension they may:</p><ul><li>&nbsp;Feel or be sick.</li><li>&nbsp;Feel dizzy or confused.</li></ul><p><strong>If you forget to give your child Septrin Paediatric Suspension</strong></p><ul><li>&nbsp;If a dose is forgotten, your child should take it as soon as possible.</li><li>&nbsp;Do not give your child a double dose to make up for the forgotten dose.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4. Possible side effects</strong></p><p>Like all medicines, Septrin Paediatric Suspension can cause side effects, although not everybody gets them.<br />Your child may experience the following side effects with this medicine.</p><p>Stop giving your child Septrin Paediatric Suspension and tell your child&rsquo;s doctor immediately if your child has an allergic reaction. Chances of an allergic reaction is very rare (fewer than 1 in 10,000 people are affected), signs of an allergic reaction include:</p><ul><li>Difficulty in breathing.</li><li>&nbsp;Fainting.</li><li>Swelling of face.</li><li>&nbsp;Swelling of mouth, tongue or throat which may be red and painful and/or cause difficulty in swallowing.</li><li>&nbsp;Chest pain.</li><li>&nbsp;Red patches on the skin.</li></ul><p><strong>If any of the side effects listed below occur, contact your doctor immediately:</strong></p><ul><li>&nbsp;Very rare: Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported (see Warnings and precautions).</li><li>Unknown frequency: An allergic type reaction in which you may develop flu-like symptoms with fever, rash, swollen glands, and abnormal blood test results (including increased white blood cells (eosinophilia) and liver enzymes). These may be symptoms of a condition known as DRESS (Drug reaction with eosinophilia and systemic symptoms) and can be severe and life-threatening (see Warnings and precautions).</li></ul><p>Your child may also experience the following side effects with this medicine:</p><p><strong>Very Common (more than 1 in 10 people)</strong></p><ul><li>&nbsp;High levels of potassium in your blood, which can cause abnormal heart beats (palpitations).</li></ul><p><strong>Common (less than 1 in 10 people)</strong></p><ul><li>&nbsp;A fungal infection called thrush or candidiasis which can affect the mouth or vagina.</li><li>&nbsp;Headache.</li><li>&nbsp;Feeling sick (nausea).</li><li>&nbsp;Diarrhoea.</li><li>&nbsp;Skin rashes.</li></ul><p><strong>Uncommon (less than 1 in 100)</strong></p><ul><li>&nbsp;Being sick (vomiting).</li></ul><p><strong>Very Rare (less than 1 in 10,000 people)</strong></p><ul><li>&nbsp;Fever (high temperature) or frequent infections.</li><li>Sudden wheeziness or difficulty breathing.</li><li>&nbsp;Mouth ulcers, cold sores and ulcers or soreness of the tongue.</li><li>&nbsp;Skin lumps or hives (raised, red or white, itchy patches of skin).</li><li>&nbsp;Blisters on the skin or inside the mouth, nose, vagina or bottom.</li><li>&nbsp;Inflammation of the eye which causes pain and redness.</li><li>&nbsp;The appearance of a rash or sunburn when your child has been outside (even on a cloudy day).</li><li>&nbsp;Low levels of sodium in the blood.</li><li>&nbsp;Changes in blood tests(low blood cell counts).</li><li>Feeling weak, tired or listless, pale skin (anaemia).</li><li>&nbsp;Heart problems.</li><li>&nbsp;Jaundice (the skin and the whites of the eyes turn yellow). This can occur at the same time as unexpected bleeding or bruising.</li><li>&nbsp;Pains in the stomach, which can occur with blood in the faeces (poo).</li><li>&nbsp;Pains in the chest, muscles or joints and muscle weakness.</li><li>Arthritis.</li><li>&nbsp;Problems with the urine. Difficulty passing urine. Passing more or less urine than usual. Blood or cloudiness in the urine.</li><li>Kidney problems.</li><li>&nbsp;Sudden headache or stiffness of the neck, accompanied by fever (high temperature).</li><li>&nbsp;Problems controlling movements.</li><li>&nbsp;Fits (convulsions or seizures).</li><li>Feeling unsteady or giddy.</li><li>&nbsp;Ringing or other unusual sounds in the ears.</li><li>&nbsp;Tingling or numbness in the hands and feet.</li><li>&nbsp;Seeing strange or unusual sights (hallucinations).</li><li>Depression.</li><li>&nbsp;Muscle pain and/or muscle weakness in HIV patients.</li><li>&nbsp;Cough.</li><li>&nbsp;Loss of appetite.</li><li>&nbsp;Hypoglycaemia (an abnormally low level of glucose in the blood).</li><li>&nbsp;Pseudomembranous colitis (Acute inflammation of the small and large intestinal mucosa with formation of pseudomembranous plaques over superficial ulceration.).</li><li>&nbsp;Pancreatitis (Acute inflammation of the pancreas).</li><li>&nbsp;Vertigo (An illusion of movement, either of the external world revolving around the individual or of the individual revolving in space).</li><li>Hepatic necrosis (which may be fatal) (breakdown/death of liver tissue).</li></ul><p><strong>Unknown frequency (cannot be estimated from the available data)</strong></p><ul><li>&nbsp;Psychotic disorder (a mental state in which you may lose touch with reality)</li></ul><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your child&rsquo;s doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5. How to store Septrin Paediatric Suspension</strong></p><ul><li>&nbsp;Keep this medicine out of the reach and sight of children.</li><li>&nbsp;Keep the bottle in the outer carton in order to protect from light.</li><li>&nbsp;Store the bottle in the outer carton.</li><li>&nbsp;Do not store above 25&ordm;C.</li><li>Once opened, use within 6 weeks.</li><li>&nbsp;Do not use the suspension after the expiry date shown on the bottle label and carton.</li><li>&nbsp;Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. What Septrin Paediatric Suspension contains</strong><br />- Septrin Paediatric Suspension is made up of two different medicines called sulfamethoxazole and trimethoprim. Each 5 ml of Septrin Paediatric Suspension contains 200 mg sulfamethoxazole and 40 mg trimethoprim.<br />- The other ingredients of Septrin Paediatric suspension are:<br />sorbitol solution (E420), glycerol (E422), dispersible cellulose (E460), carmellose sodium, methyl hydroxybenzoate (E218), sodium benzoate (E211), saccharin sodium (E954), ethanol (alcohol), vanilla flavour containing sulphur dioxide (E220), banana flavour, polysorbate 80 (E433) and purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                b. What Septrin Paediatric Suspension looks like and contents of the pack
Septrin Paediatric Suspension is supplied to you in an amber-coloured glass bottle, containing 100 ml or 50 ml of an off-white banana and vanilla flavoured syrup. The medicine comes with a double-ended measuring spoon. One end of the spoon will give you 5 ml of the suspension and the other will give you 2.5 ml.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>c. Marketing Authorisation Holder and Manufacturer</strong></p><p><strong>Marketing authorisation holder</strong><br />Aspen Pharma Trading Limited<br />3016 Lake Drive,<br />Citywest Business Campus,<br />Dublin 24,<br />Ireland</p><p><strong>Manufacturer</strong><br />Aspen Bad Oldesloe GmbH<br />Industriestrasse 32-36,<br />D-23843 Bad Oldesloe,<br />Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d. This leaflet was last revised in {September/ 2020}Version{3}
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>1. ما هو معلق سبترين للأطفال وما هي دواعي استخدامه</strong><br />معلق فموي سبترين للأطفال 40 ملغ/ 200 ملغ لكل 5 مل (يطلق عليه &quot;معلق سبترين للأطفال&quot; في هذه النشرة) هو مركب من مضادين حيويين مختلفين، يسميان سالفاميثوكسازول وتريميثوبريم، ويُستخدم في علاج العدوى الناجمة عن البكتريا. يسمى هذا الدواء المركب أيضا كوتريموكسازول. مثل جميع<br />مضادات الحيوية، يعمل معلق سبترين للأطفال فقط لعلاج أنواع محددة من البكتريا. وهذا يعني أن الدواء مناسب فقط لعلاج بعض أنواع العدوى.</p><p>يمكن استخدام معلق سبترين للأطفال لعلاج أو الوقاية من:</p><ul><li>&nbsp;العدوى الرئوية (الالتهاب الرئوي) الناجمة عن الكائنات المجهرية، المتكيسة الرئوية الجؤجؤية (تُعرف سابقا ب Pneumocystis carinii )(البعض يطلق عليها الالتهاب الرئوي بالمتكيسة الجؤجؤية( PJP )).</li></ul><p>يمكن استخدام معلق سبترين للأطفال لعلاج:</p><ul><li>عدوى المثانة أو التهابات المسالك البولية (عدوى الجهاز البولي).</li><li>&nbsp;عدوى الجهاز التنفسي مثل التهاب الشعب الهوائية.</li><li>عدوى الأذن مثل التهاب الأذن الوسطى.</li><li>&nbsp;عدوى تُعرف باسم داء النوكارديات، والتي يمكن أن تُصيب الرئتين والجلد والمخ.</li><li>&nbsp;العدوى التي تتسبب بها بكتيريا تُعرف باسم التوكسوبلازما (داء المقوسات).</li><li>&nbsp;عدوى تسمى داء البروسيلات، إن لم تحدث العلاجات الأخرى مفعولاً وبالإضافة إلى مضادات أخرى تتماشى مع المبادئ التوجيهية الوطنية للعلاج.</li></ul><p>ينبغي الاهتمام بالإرشادات الرسمية المتعلقة بالاستخدام الملائم لمضادات البكتيريا.</p><p>يوصف معلق سبترين للأطفال لعلاج الأطفال من عمر 12 عاما فأقل(الرضع &gt; 6 أسابيع إلى &lt; عامين) والأطفال (&gt; عامين إلى &lt; 12 عاما) .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>2. ما الذي يجب أن تعرفه قبل أن يتناول طفلك معلق سبترين للأطفال</strong></p><p><strong>يجب ألا يتناول طفلك معلق سبترين للأطفال في الحالات التالية :</strong></p><ul><li>&nbsp;إذا كان مصابا بحساسية من المواد الفعالة وهي سالفاميثوكسازول، أو ترايميثوبريم أو كوتريموكسازول أو أي من مكونات الدواء الأخرى(المذكورة في القسم 6).</li><li>&nbsp;إذا كان حساسا لأدوية السلفوناميد . من ضمن هذه الأدوية السلفونيليوريا (مثل جليكلازايد وجليبنكلاميد) أو مدرات البول من فئة الثيازيد (مثلبيندروفلوميثازيد- أقراص مدرة للبول).</li><li>&nbsp;إذا كان مصابا بمشاكل كبدية أو كلوية حادة.</li><li>&nbsp;إذا أصيب من قبل بمشكلة في الدم تسببت في كدمات أو نزيف (قلة الصفائح الدموية).</li><li>&nbsp;إذا تم تشخيص حالتك بالإصابة بمرض نادر في الدم يُدعى البُرْفيرِيَّة، والذي قد يؤثر على الجلد أو الجهاز العصبي.</li><li>يُمنع استعمال معلق سبترين للأطفال لحديثي الولادة خلال الأسابيع ال 6 الأولى من حياتهم.</li></ul><p>إن لم تكن متأكداً أن أيا مما ورد أعلاه ينطبق على طفلك، تحدث إلى طبيب طفلك أو الصيدلي قبل أن يتناول الطفل معلق سبترين للأطفال.</p><p><strong>التحذيرات والاحتياطات</strong><br />تم تسجيل الإصابة بطفح جلدي خطير مهدد للحياة مثل (متلازمة ستيفنز جونسون، تقشر الأنسجة المتموتة البشروية التسممي)، وتفاعلات دوائية مصحوبة بكثرة اليوزينيات وأعراض جهازية (DRESS)مع معلق سبترين للأطفال، وتبدأ الأعراض في صورة بقع أو نقط حمراء أو بقع دائرية وتظهر في الغالب<br />مصحوبة ببثور في منطقة الجذع. تتضمن العلامات الإضافية التي يجب تفقدها ظهور قرح في الفم، والحلق، والأنف، والأعضاء التناسلية والتهاب الملتحمة (انتفاخ واحمرار العينين). تظهر عادةً نوبات الطفح الجلدي المُهددة للحياة هذه مصحوبة بأعراض تشبه أعراض الإنفلونزا، بما في ذلك الحمى. قد يتفاقم<br />الطفح الجلدي ويؤدي إلى انتشار البثور أو تقشر الجلد. يكون الاحتمال الأعلى لحدوث تفاعلات الجلد الخطيرة خلال الأسابيع الأولى من العلاج، لكنها قد تستمر ل 8 أسابيع بعد تناول الدواء وتتفاقم في حالات إلى كثرة اليوزينيات وأعراض جهازية (DRESS)(راجع القسم 4 ).</p><p>إذا أصيب طفلك بمتلازمة ستيفنز جونسون، أو تقشر الأنسجة المتموتة البشروية التسممي أو كثرة اليوزينيات وأعراض جهازية مع استخدام ملق سبترين للأطفال، يجب ألا يعاود طفلك تناول هذا الدواء بأي وقت . إذا أُصيب طفلك بطفح جلدي أو هذه الأعراض الجلدية، توقف عن إعطائه معلق سبترين للأطفال<br />واستشر طبيبك على الفور وأخبره أن طفلك يتناول هذا الدواء.</p><p>تحدث مع طبيب طفلك أو الصيدلي قبل إعطائه معلق سبترين للأطفال في الحالات التالية:</p><ul><li>&nbsp;إذا كان مصابا بحساسية شديدة أو بمرض الربو القصبي.</li><li>&nbsp;إذا علمت أن طفلك مُعرض للإصابة باضطراب نادر في الدم يُدعى البُرْفيرِيَّة.</li><li>&nbsp;إذا كان يعاني من نقص في حمض الفوليك (نوع من الفيتامينات) في الجسم- مما قد يؤدي إلى شحوب الجلد والشعور بالإجهاد والضعف وانقطاع النفس. وهذا يعرف بالأنيميا (فقر الدم).</li><li>&nbsp;إذا كان مصابا بمرض يُدعى نقص إنزيم سداسي فوسفات الجلوكوز النازع للهيدروجين الذي قد يؤدي إلى الإصابة باليرقان أو التدمير التلقائي لكرات الدم الحمراء .</li><li>&nbsp;إذا كان يعاني من مشكلة في عملية الأيض تُدعى بيلة الفينيل كيتون ولا يتبع نظاما غذائيا مُخصصا لعلاج هذه الحالة.</li><li>إذا كان يعاني من النحافة أو سوء التغذية.</li><li>إذا أخبرك طبيب طفلك أن مستويات البوتاسيوم في الدم مرتفعة لدى طفلك أو إذا كان طفلك يتناول أدوية قد ترفع مستويات البوتاسيوم في دمه، مثلمدرات البول (أقراص الماء التي تساعد على زيادة كمية البول التي ينتجها) والسترويدات(مثل بريدنيزولون) والديجوكسين. فارتفاع مستوى البوتاسيوم في دم طفلك قد يؤدي إلى اضطراب ضربات القلب (الخفقان)، أو الغثيان، أو الدوّار أو الصداع.</li><li>&nbsp;أخبرك طبيب طفلك أن مستوى الصوديوم في دم طفلك منخفض بشكل غير طبيعي.</li><li>أخبرك طبيب طفلك أن طفلك مصاب بأي اضطرابات خطيرة في الدم والأنسجة المكوّنة للدم (اضطرابات دموية). على سبيل المثال انخفاض تعداد خلايا الدم.</li><li>&nbsp;إذا كان مصابا بمرض كلوي.</li></ul><p><strong>الأدوية الأخرى ومعلق سبترين للأطفال</strong><br />أخبر طبيب طفلك أو الصيدلي إن كان طفلك يتناول أو تناول مؤخراً أو قد يتناول أي أدوية أخرى. هذا لأن معلق سبترين للأطفال قد يؤثر على آلية عمل بعض الأدوية الأخرى. كما يمكن للأدوية الأخرى أن تؤثر على آلية عمل معلق سبترين للأطفال.<br />أخبر طبيب طفلك أو الصيدلي على وجه الخصوص إذا كان طفلك يتناول أيًا من الأدوية التالية:</p><ul><li>&nbsp;مدرات البول (أقراص الماء)، التي تساعد على زيادة كمية البول التي يتنجها الجسم.</li><li>&nbsp;بيريميثامين، يُستخدم لعلاج الملاريا والوقاية منها ولعلاج الإسهال.</li><li>&nbsp;السيكلوسبورين، يُستخدم بعد عمليات زرع الأعضاء.</li><li>&nbsp;مرققات الدم مثل الوارفارين .</li><li>&nbsp;فينيتوين، يُستخدم في علاج الصرع (نوبات الصرع).</li><li>&nbsp;الأدويةالمستخدمة في علاج داء السكري مثل جليبنكلاميد أو جليبيزيد أو تولبوتاميد (السلفونيليوريا) وريباجلينيد.</li><li>&nbsp;الأدوية التي تُستخدم في علاج المشكلات المتعلقة بطريقة نبض القلب مثل ديجوكسين أو بروكاييناميد.</li><li>&nbsp;أمانتدين، يُستخدم في علاج مرض باركنسون ومرض التصلب المتعدد والأنفلونزا ومرض الحزام الناري.</li><li>&nbsp;الأدوية المُستخدمة في علاج فيروس نقص المناعة المُكتسبة (HIV)، مثل دواء يُدعى زيدوفيدين أو لاميفودين.</li><li>الأدوية التي يمكن أن ترفع مستوى البوتاسيوم في الدم، مثل الأدوية المدرة للبول (أقراص الماء، التي تساعد على زيادة كمية البول التي ينتجها الجسم، مثل سبيرونولاكتون)، الستيرويدات(مثل البريدنيزولون) والديجوكسين.</li><li>&nbsp;أزاثيوبرين الذي قد يُقدم للمرضى بعد زرع الأعضاء أو لعلاج اضطرابات الجهاز المناعي أو مرض معوي التهابي.</li><li>ميثوتريكسات، وهو دواء يُستخدم لعلاج بعض أنواع السرطان وبعض الأمراض التي تؤثر على الجهاز المناعي.</li><li>&nbsp;ريفامبيسين، مضاد حيوي.</li><li>&nbsp;حمض الفولينيك.</li><li>&nbsp;أدوية منع الحمل.</li></ul><p><strong>معلق سبترين مع الطعام و الشراب</strong><br />يجب أن يتناول طفلك معلق سبترين للأطفال مع بعض الطعام أو الشراب. وذلك منعا للشعور بالغثيان (الرغبة في القئ) أو الإصابة بالإسهال. رغم أنه من الأفضل تناوله مع الطعام، إلا أنه لا يزال بإمكان الطفل تناوله على معدة خاوية.<br />احرص على جعل طفلك يتناول كمية وافرة من السوائل مثل الماء أثناء تناول معلق سبترين للأطفال.</p><p><u><strong>يحتوي معلق سبترين للأطفال على السواغات التالية بآثار معروفة:</strong></u></p><ul><li>&nbsp;6.5 غرام من 70 % محلول سوربيترول (غير متبلور)في 10 مل معلق، يعادل 4.55 غ من سوربيترول لكل 10 مل السوربيترول من مصادر الفركتوز. إذا أخبرك الطبيب أنك (أو طفلك) مصاب بعدم تحمل بعض أنواع السكر أو تم تشخيصك بعدم التحمل الوراثي للفركتوز( HFI )، وهو اضطراب جيني نادر لا يستطيع به الفرد تكسير الفركتوز، تحدث إلى طبيبك قبل أن تتناول (أو تقدم لطفلك) هذا الدواء. قد يتسبب السوربيترول في عدم ارتياح معدي معوي وتأثير ملين طفيف.</li><li>القيمة الحرارية 2.6 كليو سعر/غ سوربيترول.</li><li>10 ملغ من بنزوات الصوديوم ( E 211) في كل جرعة 10 مل مما يعادل 0.75 من بنزوات الصوديوم لكل كجم من وزن الجسم.</li><li>&nbsp;كميات صغيرة من الإيثانول (كحول)، أقل من 100 ملغ لكل ملعقة 5 مل (أقل من 100 ملغ لكل 10 جرعة 10 مل) .</li><li>&nbsp;ميثيل بي- هيدروكسي بنزوات (E 218)، الذي قد يتسبب في تفاعلات تحسسية (يحتمل أن تكون مؤجلة).</li><li>&nbsp;10 ملغ من بنزوات الصوديوم (E 211) في كل جرعة 10 مل.</li><li>1 ملغ/ 1مل، قد يرفع احتمال الإصابة باليرقان (اصفرار الجلد والعينين) في حديثي الولادة (حتى عمر 4 أسابيع).</li><li>&nbsp;أقل من 1 مليمول من الصوديوم (23 ملغ) لكل جرعة 10 مل، أي أنه في الأساس &quot;خال من الصوديوم&quot;.</li><li>&nbsp;تحتوي نكهة الفانيليا على ثاني أكسيد الكبريت(E220) الذي قد يؤدي في حالات نادرة إلى تفاعلات فرط حساسية خطيرة وتشنج قصبي.</li></ul><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>3. كيفية تقديم معلق سبترين للأطفال</strong><br />احرص دائما على تناول الطفل معلق سبترين للأطفال وفقا لتعليمات الطبيب أو الصيدلي بدقة. استشر طبيب الطفل أو الصيدلي إن لم تكن متأكدًا.</p><p><strong>الجرعة المعيارية</strong><br />الجرعات المعيارية التي يُنصح بها في حالات العدوى الحادة</p><p><strong>الأطفال من عمر 12 عاماً فأقل (الرضع &gt; 6 أسابيع إلى &lt; عامين) والأطفال (&gt; عامين إلى &lt; 12 عاماً). :</strong></p><p>تُحدد جرعات الأطفال بحسب عمر الطفل ووزنه كما هو موضح بالجدول أدناه :</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:983px"><tbody><tr><td colspan="2" style="vertical-align:top; width:980px"><p dir="RTL">الجرعة المعيارية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">السن</p></td><td style="vertical-align:top; width:621px"><p dir="RTL">معلق الأطفال</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">من 6 أعوام إلى 12 عاماً.</p></td><td style="vertical-align:top; width:621px"><p dir="RTL">ملعقتان بسعة 5 مل صباحاً وملعقتان بسعة 5 مل مساءً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">من 6 أشهر إلى 5 أعوام.</p></td><td style="vertical-align:top; width:621px"><p dir="RTL">ملعقة بسعة 5 مل صباحاً وملعقة بسعة 5 مل مساءً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">من 6 أسابيع إلى 5 أشهر.</p></td><td style="vertical-align:top; width:621px"><p dir="RTL">ملعقة بسعة 2.5 مل صباحاً وملعقة بسعة 2.5 مل مساءً</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">&nbsp;</p></td><td style="vertical-align:top; width:621px"><p dir="RTL">الجرعة للأطفال تكافئ حوالي 6 ملغ تريميثوبريم و30 ملغ سالفاميثوكسازول لكل كيلو جرام من وزن الجسم.</p><p dir="LTR">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><ul><li>يجب تناول معلق سبترين للأطفال لمدة خمسة أيام على الأقل .</li><li>&nbsp;تأكد من إتمام الطفل الدورة العلاجية بمعلق سبترين للأطفال التي وصفها الطبيب .</li></ul><p><strong>الجرعة الخاصة</strong><br />تُحدد جرعة معلق سبترين للأطفال وطول مدة العلاج به بحسب العدوى لدى الطفل ودرجة حدتها. قد يصف طبيب طفلك جرعة مختلفة أو دورة علاجية بمدةمختلفة بمعلق سبترين للأطفال للأسباب التالية:</p><ul><li>&nbsp;لعلاج التهابات المسالك البولية.</li><li>&nbsp;لعلاج والوقاية من العدوى الرئوية الناجمة عن بكتريا المتكيسة الرئوية الجؤجؤية&nbsp; (PJP) .</li><li>&nbsp;علاج الإلتهابات الناجمة عن بكتريا التوكسوبلازما (داء المقوسات) أو البروسيلا (داء البروسيلات).</li></ul><p>إذا كان طفلك مصابا بمشاكل كلوية، قد يقوم الطبيب بالتالي :</p><ul><li>&nbsp;وصف جرعة أقل من معلق سبترين للأطفال.</li><li>أخذ عينات من الدم لإجراء الفحوصات لمعرفة ما إذا كان الدواء يعمل بالشكل الصحيح أم لا.</li></ul><p><strong>إذا كان طفلك يتناول معلق سبترين للأطفال منذ فترة طويلة، قد يقوم طبيبك بما يلي:</strong></p><ul><li>&nbsp;أخذ عينات من الدم لإجراء الفحوصات لمعرفة ما إذا كان الدواء يعمل بالشكل الصحيح أم لا.</li><li>&nbsp;وصف حمض الفوليك (فيتامين) لتتناوله بالتزامن مع معلق سبترين للأطفال.</li></ul><p><strong>في حالة تناول طفلك جرعة أكثر من اللازم من معلق سبترين للأطفال</strong><br />إذا تناول طفلك جرعة أكثر من اللازم من معلق سبترين للأطفال، تحدث إلى طبيب الطفل أو اذهب إلى المستشفى فورًا. وخذ عبوة الدواء معك.<br />إذا تناول طفلك جرعة أكثر من اللازم من معلق سبترين للأطفال، قد يظهر عليه التالي:</p><ul><li>&nbsp;الشعور بالغثيان أو القيء</li><li>&nbsp;الشعور بالدوار أو الارتباك</li></ul><p><strong>إذا نسيت أن تقدم لطفلك معلق سبترين للأطفال</strong></p><ul><li>&nbsp;في حالة نسيان جرعة، يجب على طفلك تناولها في أقرب وقت ممكن.</li><li>&nbsp;لا تقدم لطفلك جرعة مضاعفة لتعويض الجرعة التي نسيتها.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>4. الآثار الجانبية المحتملة</strong><br />مثل جميع الأدوية، يمكن أن يسبب معلق سبترين للأطفال آثاراً جانبية، على الرغم من أنه ليس بالضرورة أن يعاني منها الجميع.<br />قد تظهر على طفلك الآثار الجانبية التالية عند تناول هذا الدواء.</p><p>توقف عن تقديم معلق سبترين لطفلك وأخبر طبيب الطفل على الفور إذا ما ظهر عليه رد فعل تحسسي. من النادر جداً حدوث رد فعل تحسسي (أقل منشخص واحد من كل 10000 شخص يصاب بهذه الحالة)، تتضمن علامات رد الفعل التحسسي الآتي:</p><ul><li>&nbsp;صعوبة في التنفس.</li><li>&nbsp;إغماء</li><li>&nbsp;تورم الوجه.</li><li>&nbsp;تورم الفم أو اللسان أو الحلق الذي قد يتحول إلى اللون الأحمر ويُسبب ألم و/أو صعوبة في البلع.</li><li>ألم الصدر.</li><li>بقع حمراء على الجلد.</li></ul><p>في حالة ظهور أي من الآثار الجانبية أدناه، اتصل بالطبيب على الفور:</p><ul><li>&nbsp;نادرة جدًا: تم الإبلاغ عن الإصابة بطفح جلدي خطير مهدد للحياة (متلازمة ستيفنز جونسون، تقشر الأنسجة المتموتة البشروية التسممي) (راجع التحذيرات والاحتياطات).</li><li>&nbsp;معدل تكرار غير معروف: رد فعلي تحسسي قد تظهر به أعراض تشبه الإنفلونزا مصحوب بحمى، طفح جلدي، وتورم الغدد، ونتائج اختبارات دم غير طبيعية (بما في ذلك ارتفاع تعداد خلايا الدم البيضاء (كثرة اليوزينيات) وإنزيمات الكبد) . قد تكون هذه أعراض حالة تُعرف ب DRESS ، وهي تفاعلات دوائية مصحوبة بكثرة اليوزينيات وأعراض جهازية وقد تكون خطيرة ومهددة للحياة (راجع التحذيرات والاحتياطات).</li></ul><p>قد تظهر على طفلك الآثار الجانبية التالية عند تناول هذا الدواء:</p><p><strong>شائعة جداً(تؤثر على أكثر من 1 من كل 10 أشخاص)</strong></p><ul><li>&nbsp;ارتفاع مستوى البوتاسيوم في الدم، مما قد يؤدي إلى اضطراب ضربات القلب(الخفقان).</li></ul><p><strong>شائعة (تؤثر على أقل من 1 من كل 10 أشخاص):</strong></p><ul><li>عدوى فطرية تُعرف باسم السلاق أو داء المبيضات، والذي قد يُصيب الفم أو المهبل.</li><li>&nbsp;صداع.</li><li>&nbsp;غثيان.</li><li>إسهال.</li><li>&nbsp;طفح جلدي.</li></ul><p><strong>غير شائعة (تؤثر على أقل من 1 من كل 100 شخص)</strong></p><ul><li>قيء</li></ul><p><strong>نادرة جداً (تؤثر على أقل من 1 من كل 10000 شخص):</strong></p><ul><li>&nbsp;حمى (ارتفاع درجة الحرارة) أو الالتهابات المتكررة.</li><li>&nbsp;أزير مفاجئ أو صعوبة في التنفس.</li><li>&nbsp;قرح الفم و قرح الزكام و قرح أو احتقان اللسان.</li><li>كتل بالجلد أو شرى(بقع جلدية مرتفعة بيضاء أو حمراء وتسبب حكة).</li><li>&nbsp;بثور على الجلد أو داخل الفم أو الأنف أو المهبل أو المقعدة.</li><li>&nbsp;التهاب العين مما قد يُسبب ألما واحمراراً.</li><li>&bull; ظهور طفح جلدي أو حروق الشمس عند الخروج من المنزل (حتى في الأيام الغائمة).</li><li>&nbsp;انخفاض مستويات الصوديوم في الدم.</li><li>&nbsp;تغيرات في نتائج الدم (انخفاض تعداد خلايا الدم).</li><li>&nbsp;الشعور بالضعف والتعب أو الفتور وشحوب لون الجلد (أنيميا).</li><li>&nbsp;مشكلات قلبية.</li><li>&nbsp;يرقان (اصفرار الجلد وبياض العيون). يمكن أن يحدث هذا في نفس وقت حدوث النزيف أو الكدمات غير المتوقعة.</li><li>&nbsp;ألم في المعدة، والذي قد يتصاحب مع تواجد الدم في البراز (الغائط)</li><li>&nbsp;ألم في الصدر أو العضلات أو المفاصل وضعف العضلات.</li><li>&nbsp;التهاب المفاصل.</li><li>&nbsp;مشكلات في البول. صعوبة في التبول. إخراج كمية أقل أو أكثر من المعتادة من البول. وجود دم أو ضبابية في البول.</li><li>&nbsp;مشكلات كلوية.</li><li>&nbsp;صداع مفاجئ أو تيبس في الرقبة مصحوبا بحمى (ارتفاع في درجة الحرارة).</li><li>&nbsp;مشاكل في التحكم في حركات الجسم.</li><li>&nbsp;نوبات (تشنجات أو اختلاج) .</li><li>&nbsp;الشعور بعدم الاتزان أو الدوخة.</li><li>&nbsp;سماع صوت رنين أو أي أصوات أخرى غريبة في الأذنين.</li><li>&nbsp;الإحساس بالوخز أو الخدر في اليدين والقدمين.</li><li>رؤية أشياء غريبة أو مشاهد غير مألوفة (هلاوس بصرية).</li><li>&nbsp;اكتئاب.</li><li>&nbsp;ألم في العضلات و/أو ضعف في العضلات في مرضي فيروس نقص المناعة المكتسبة(الإيدز).</li><li>&nbsp;السعال.</li><li>&nbsp;فقدان الشهية.</li><li>&nbsp;نقص سكر الدم (انخفاض غير طبيعي في مستوى الجلوكوز في الدم).</li><li>&nbsp;التهاب القولون الغشائي الكاذب (التهاب حاد في الغشاء المخاطي للأمعاد الدقيقة والغليظة مع تكون لويحات غشائية كاذبة فوق التقرح السطحي).</li><li>&nbsp;التهاب البنكرياس (التهاب حاد في البنكرياس).</li><li>&nbsp;الدوخة (التوهم بالحركة، إما حركة العالم الخارجي حول الفرد أو حركة الفرد نفسه في الفراغ).</li><li>&nbsp;النخر الكبدي (يمكن أن يكون مميتا) (تكّسر/موت الخلايا الكبدية).</li></ul><p><strong>معدل تكرار غير معروف (لا يمكن تقدير مدى التكرار من البيانات المتوفرة)</strong>:</p><ul><li>&nbsp;اضطراب ذهاني (حالة عقلية قد تفقد فيها التواصل مع العالم الواقعي).</li></ul><p>في حال أصبحت أي من هذه الأعراض الجانبية خطرة، أو إن لاحظت أي أعراض جانبية غير مذكورة في هذه النشرة، يرجى إخبار طبيب طفلك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>5 . كيفية تخزين معلق سبترين للأطفال</strong></p><ul><li>&nbsp;يُحفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</li><li>&nbsp;تُحفظ الزجاجة في العلبة الكرتونية الخارجية لحمايتها من الضوء.</li><li>&nbsp;تُخزن الزجاجة في العلبة الكرتونية الخارجية.</li><li>&nbsp;لا يُخزن في درجة حرارة أعلى من 25 درجة مئوية.</li><li>&nbsp;بمجرد فتح الزجاجة، يجب استخدام الدواء خلال 6 أسابيع.</li><li>&nbsp;لا تتناول المعلق بعد تاريخ انتهاء الصلاحية الموضح على ملصق الزجاجة والعلبة الكرتونية.</li><li>&nbsp;لا يجب التخلص من أي أدوية في ماء الصرف الصحي أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ. محتويات معلق سبرتين للأطفال</strong><br />- يتكون معلق سبترين للأطفال من دوائيين مختلفين هما سالفاميثوكسازول وترايميثوبريم. يحتوي كل 5 مل من معلق سبرتين للأطفال على 200 ملغ من سالفاميثوكسازول و 40 ملغ من ترايميثوبريم.<br />- المكونات الأخرى لمعلق سبترين للأطفال هي:<br />محلول سوربيترول (E420) ، غليسرول (E422)، سيللوز قابل للانتشار (E460)، كارميلوز صوديوم، ميثيل هيدروكسي بنزوات (E218)، بنزوات صوديوم (E211)، سكارين صوديوم (E954)، إيثانول(كحول)، نكهة الفانيليا تحتوي ثاني أكسيد الكبريت (E220)، نكهة موز ، بوليسوربات 80 (E433)وماء منقى .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>ب. كيف يبدو معلق سبترين للأطفال وما هي محتويات العبوة</strong><br />يُورد معلق سبترين للأطفال في عبوة زجاجية كهرمانية اللون، ويحتوي على 100 مل أو 50 مل من شراب مائل للصفرة بنكهة الموز والفانيليا. ويأتي مزوداً بملعقة قياس ذات طرفين، يعطيك أحد طرفي الملعقة قياس 5 مل من المعلق ويعطيك الطرف الآخر قياس 2.5 مل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>ت. مالك حق التسويق والمُصَّنع</strong></p><p><strong>مالك حق التسويق</strong><br />أسبن فارما تريدينغ المحدودة<br />3016 ليك درايف،<br />مجمع سيتي ويست للأعمال،<br />دبلن 24 ،<br />أيرلندا</p><p><strong>الشركة المصنعة</strong><br />شركة أسبن باد أولدسلو المحدودة<br />المنطقة الصناعية 32 - 36<br />دي - 23843 باد أولدسلو،<br />ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ث . تمت آخر مراجعة لهذه النشرة في {سبتمبر / 2020} ، النسخة {3}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Septrin Paediatric 40 mg/200 mg per 5 ml Oral Suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 ml contains 40 mg Trimethoprim and 200 mg Sulfamethoxazole.

Excipients with known effect:
Contains 3250 mg of sorbitol (E 420) per 5 ml, 13.50 μL of ethanol per 5 ml, 5 mg of methyl hydroxybenzoate (E218) per 5 ml, 10.95 mg of sodium per 5 ml (inclusive of 5mg of sodium benzoate E 211), vanilla flavour with 0.00015 μL sulphur dioxide per 5 ml and 750 mg of glycerol per 5ml.

For the full list of excipients, see section 6.1,
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral suspension
An off-white, banana and vanilla flavoured syrup.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Septrin Paediatric Suspension is indicated in children aged 12 years and under (infants (&gt;6 weeks to &lt;2 years old) and children (&gt;2 to &lt;12 years old) for the treatment of the following infections when owing to sensitive organisms (see section 5.1) :</p><p>- Urinary tract infections: For simple urinary tract infections, trimethoprim alone or another single antimicrobial agent is the preferred treatment. Since trimethoprim is also as efficacious as Septrin for the prophylaxis of recurrent urinary tract infections, Septrin is not indicated for prophylactic use.</p><p>- Respiratory tract infections: Septrin may be used as second line therapy in chronic obstructive airways disease or other respiratory tract infections, including acute otitis media where sensitivity has been demonstrated or is highly probable. (Septrin is not indicated for prophylactic or prolonged administration in otitis media).</p><p>- Treatment and prevention of Pneumocystis jirovecii pneumonitis (PJP).</p><p>- Septrin may be used in the management of other serious conditions such as nocardiasis, toxoplasmosis and brucellosis.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p><u>Standard dosage recommendations for acute infections</u></p><p><em>Children aged 12 years and under (infants (&gt;6 weeks to &lt;2 years old) and children (&gt;2 to &lt;12 years old)</em><em> :</em></p><p>The standard dosage for children is equivalent to approximately 6 mg trimethoprim and 30 mg sulfamethoxazole per kg body weight per day, given in two equally divided doses. The schedules for children are according to the child&rsquo;s age and provided in the table below:</p><table border="1" cellspacing="0" cellpadding="0" style="width:1237px"><tbody><tr><td colspan="2" style="vertical-align:top; width:1234px"><p><strong>STANDARD DOSAGE</strong></p></td></tr><tr><td style="vertical-align:top; width:595px"><p><strong>Age</strong></p></td><td style="vertical-align:top; width:640px"><p><strong>Paediatric Suspension</strong></p></td></tr><tr><td style="vertical-align:top; width:595px"><p>6 to 12 years</p></td><td style="vertical-align:top; width:640px"><p>10&nbsp;ml every 12&nbsp;hours</p></td></tr><tr><td style="vertical-align:top; width:595px"><p>6 months to 5 years</p></td><td style="vertical-align:top; width:640px"><p>5&nbsp;ml every 12&nbsp;hours</p></td></tr><tr><td style="vertical-align:top; width:595px"><p>6 weeks to 5 months</p></td><td style="vertical-align:top; width:640px"><p>2.5&nbsp;ml every 12&nbsp;hours</p></td></tr></tbody></table><p>&nbsp;</p><p>Treatment should be continued until the patient has been symptom free for two days; acute infections will require treatment for at least 5 days. If clinical improvement is not evident after 7 days therapy, the patient should be reassessed.</p><p>As an alternative to standard dosage for acute uncomplicated lower urinary tract infections, short-term therapy of 1 to 3 days&#39; duration has been shown to be effective.</p><p><em>Impaired hepatic function:</em></p><p>No data are available relating to dosage in patients with impaired hepatic function.</p><p><em>Impaired renal function: </em></p><p><em>&nbsp;Dosage recommendation:</em></p><p><em>&nbsp;Adults (&gt;18 years old) and children over 12 years old (&gt;12 to &lt; 18 years old):</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:1266px"><tbody><tr><td style="vertical-align:top; width:601px"><p><strong>Creatinine Clearance (ml/min)</strong></p></td><td style="vertical-align:top; width:662px"><p><strong>Recommended Dosage</strong></p></td></tr><tr><td style="vertical-align:top; width:601px"><p>&gt;30</p></td><td style="vertical-align:top; width:662px"><p>10 ml every 12 hours</p></td></tr><tr><td style="vertical-align:top; width:601px"><p>15 to 30</p></td><td style="vertical-align:top; width:662px"><p>5 ml every 12 hours</p></td></tr><tr><td style="vertical-align:top; width:601px"><p>&lt;15</p></td><td style="vertical-align:top; width:662px"><p>Not recommended</p></td></tr></tbody></table><p>No information is available for children aged 12 years and under with renal failure. See section 5.2 for the pharmacokinetics in the paediatric population with normal renal function of both components of trimethoprim-sulfamethoxazole.</p><p>Measurements of plasma concentration of sulfamethoxazole at intervals of 2 to 3 days are recommended in samples obtained 12 hours after administration of Septrin. If the concentration of total sulfamethoxazole exceeds 150&nbsp;micrograms/ml then treatment should be interrupted until the value falls below 120&nbsp;micrograms/ml.</p><p><em><u>Pneumocystis jirovecii pneumonitis</u></em><em>:</em></p><p><em>Treatment - </em><em>Children aged 12 years and under (infants (&gt;6 weeks to &lt;2 years old) and children (&gt;2 to &lt;12 years old) :</em></p><p><em>&nbsp;</em>A higher dosage is recommended using 20&nbsp;mg trimethoprim and 100 mg sulfamethoxazole per kg of body weight per day (see table below) in two or more divided doses for two weeks. The aim is to obtain peak plasma or serum levels of trimethoprim of <u>greater than or equal to</u>&nbsp;5&nbsp;microgram/ml (verified in patients receiving 1-hour infusions of intravenous Septrin) (See section 4.8).</p><p><em>Prevention - </em><em>Children aged 12 years and under (infants (&gt;6 weeks to &lt;2 years old) and children (&gt;2 to &lt;12 years old):</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:1277px"><tbody><tr><td style="vertical-align:top"><p><strong>Age</strong></p></td><td style="vertical-align:top; width:895px"><p><strong>Paediatric Suspension</strong></p></td></tr><tr><td style="vertical-align:top"><p>6 to 12 years</p></td><td style="vertical-align:top; width:895px"><p>10 ml every 12 hours, seven days per week</p></td></tr><tr><td style="vertical-align:top"><p>6 to 12 years</p></td><td style="vertical-align:top; width:895px"><p>10 ml every 12 hours, three times per week on alternative days</p></td></tr><tr><td style="vertical-align:top"><p>6 to 12 years</p></td><td style="vertical-align:top; width:895px"><p>10 ml every 12 hours, three times per week on consecutive days</p></td></tr><tr><td style="vertical-align:top"><p>6 to 12 years</p></td><td style="vertical-align:top; width:895px"><p>20 ml once a day, three times per week on consecutive days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:895px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>6 months to 5 years</p></td><td style="vertical-align:top; width:895px"><p>5 ml every 12 hours, seven days per week</p></td></tr><tr><td style="vertical-align:top"><p>6 months to 5 years</p></td><td style="vertical-align:top; width:895px"><p>5 ml every 12 hours, three times per week on alternative days</p></td></tr><tr><td style="vertical-align:top"><p>6 months to 5 years</p></td><td style="vertical-align:top; width:895px"><p>5 ml every 12 hours, three times per week on consecutive days</p></td></tr><tr><td style="vertical-align:top"><p>6 months to 5 years</p></td><td style="vertical-align:top; width:895px"><p>10 ml once a day, three times per week on consecutive days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:895px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>6 weeks to 5 months</p></td><td style="vertical-align:top; width:895px"><p>2.5 ml every 12 hours, seven days per week</p></td></tr><tr><td style="vertical-align:top"><p>6 weeks to 5 months</p></td><td style="vertical-align:top; width:895px"><p>2.5 ml every 12 hours, three times per week on alternative days</p></td></tr><tr><td style="vertical-align:top"><p>6 weeks to 5 months</p></td><td style="vertical-align:top; width:895px"><p>2.5 ml every 12 hours, three times per week on consecutive days</p></td></tr><tr><td style="vertical-align:top"><p>6 weeks to 5 months</p></td><td style="vertical-align:top; width:895px"><p>5 ml once a day, three times per week on consecutive days</p></td></tr></tbody></table><p>The daily dose given on a treatment day approximates to 150 mg trimethoprim/m2/day and 750 mg sulfamethoxazole/m2/day. The total daily dose should not exceed 320 mg trimethoprim and 1600 mg sulfamethoxazole.</p><p><em>Nocardiosis</em></p><p>There is no consensus on the most appropriate dosage. Adult doses of 480 mg trimethoprim/2400 mg sulfamethoxazole to 640 mg trimethoprim/3200 mg sulfamethoxazole daily for up to three months have been used.</p><p><em>Brucellosis</em></p><p>It may be advisable to use a higher than standard dosage initially. Treatment should continue for a period of at least four weeks and repeated courses may be beneficial. Septrin should be given in combination with other agents in line with national treatment guidelines.</p><p><em>Toxoplasmosis</em></p><p>There is no consensus on the most appropriate dosage for the treatment or prophylaxis of this condition. The decision should be based on clinical experience. Doses of 480 mg or 960 mg of trimethoprim - sulfamethoxazole twice daily for three months have been used for prophylaxis and 40 mg/kg/day or 120 mg/kg/day for a mean of 25 days for the treatment of toxoplasmosis in patients with HIV.</p><p><u>Method of administration</u></p><p>Oral</p><p>It may be preferable to take Septrin with some food or drink to minimise the possibility of gastrointestinal disturbances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Septrin Paediatric suspension is contraindicated in patients with:
• hypersensitivity to the active substance(s) sulphonamides, trimethoprim or to any of the excipients listed in section 6.1.
• severe renal insufficiency where repeated measurements of the plasma drug concentration cannot be performed.
• severe impairment of liver function.
• a history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulphonamides.
• acute porphyria.
Septrin should not be given to infants during the first 6 weeks of life.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fatalities, although very rare, have occurred due to severe reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anaemia, other blood dyscrasias and hypersensitivity of the respiratory tract.</p><p><u>Life threatening adverse reaction</u></p><ul><li>&nbsp;Life-threatening cutaneous reactions Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia with systemic symptoms (DRESS) have been reported with the use of Septrin.</li><li>&nbsp;Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of SJS or TEN is within the first weeks of treatment and for DRESS the risk of occurrence is in the first two to eight weeks after drug administration.</li><li>&nbsp;If symptoms or signs of SJS, TEN (e.g. progressive skin rash often with blisters or mucosal lesions) or DRESS (e.g. fever, eosinophilia, rash, lymphadenopathy, abnormal blood/liver function test and/or visceral organ involvement) are present, Septrin treatment should be discontinued (see section 4.8).</li><li>The best results in managing SJS and TEN come from early diagnosis and immediate discontinuation of any suspect drug. Early withdrawal is associated with a better prognosis.</li><li>&nbsp;If the patient has developed SJS or TEN with the use of Septrin, Septrin must not be re-started in this patient at any time.</li></ul><p><u>Elderly patients</u><br />Particular care is always advisable when treating elderly patients because, as a group, they are more susceptible to adverse reactions and more likely to suffer serious effects as a result particularly when complicating conditions exist, e.g. impaired kidney and/or liver function and/or concomitant use of other drugs.</p><p><u>Patients with renal impairment</u><br />For patients with known renal impairment special measures should be adopted (see section 4.2).</p><p><u>Urinary output</u><br />An adequate urinary output should be maintained at all times. Evidence of crystalluria in vivo is rare, although sulphonamide crystals have been noted in cooled urine from treated patients. In patients suffering from hypoalbuminaemia the risk may be increased.</p><p><u>Folate</u><br />Regular monthly blood counts are advisable when Septrin is given for long periods, or to folate&nbsp;deficient patients or to the elderly; since there exists a possibility of asymptomatic changes in haematological laboratory indices due to lack of available folate. Supplementation with folinic acid may be considered during treatment but this should be initiated with caution due to possible interference with antimicrobial efficacy (see section 4.5).</p><p><u>Patients with glucose-6-phosphate dehydrogenase deficiency</u><br />In glucose-6-phosphate dehydrogenase (G-6-PD) deficient patients, haemolysis may occur.</p><p><u>Patients with severe atopy or bronchial asthma</u><br />Septrin should be given with caution to patients with severe atopy or bronchial asthma.</p><p><u>Treatment of streptococcal pharyngitis due to Group A beta-haemolytic streptococci</u><br />Septrin should not be used in the treatment of streptococcal pharyngitis due to Group A &beta;-haemolytic streptococci; eradication of these organisms from the oropharynx is less effective than with penicillin.</p><p><u>Phenylalanine metabolism</u><br />Trimethoprim has been noted to impair phenylalanine metabolism but this is of no significance in phenylketonuric patients on appropriate dietary restriction.</p><p><u>Patients with or at risk of porphyria</u><br />The administration of Septrin to patients known or suspected to be at risk of porphyria should be avoided. Both trimethoprim and sulphonamides (although not specifically sulfamethoxazole) have been associated with clinical exacerbation of porphyria.</p><p><u>Patients with hyperkalaemia and hyponatraemia</u><br />Close monitoring of serum potassium and sodium is warranted in patients at risk of hyperkalaemia and hyponatraemia.</p><p><u>Metabolic acidosis</u><br />Septrin has been associated with metabolic acidosis when other possible underlying causes have been excluded. Close monitoring is always advisable when metabolic acidosis is suspected.</p><p><u>Patients with serious haematological disorders</u><br />Except under careful supervision Septrin should not be given to patients with serious haematological disorders (see section 4.8). Septrin has been given to patients receiving cytotoxic therapy with little or no additional effect on the bone marrow or peripheral blood.</p><p><u>Excipients with known effects</u><br />Patients with rare hereditary problems of fructose intolerance should not take this medicine (see section 2).</p><p>This medicinal product contains<strong> sorbitol (E 420)</strong>. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product. Sorbitol may cause gastrointestinal discomfort and mild laxative effect. It contains 5 mg <strong>sodium benzoate (E 211)</strong> in each 5 mL ampoule, which is equivalent to 1mg/1mL and which may increase the risk of jaundice in newborn babies. This medicinal product contains also small amounts of <strong>ethanol</strong> (alcohol), less than 100 mg per 5 ml and contains less than 1 mmol sodium (23 mg) per 5 ml, that is to say essentially &lsquo;sodium free&rsquo;. It also contains<strong> sulphur dioxide (E 220)</strong>, which may rarely cause severe hypersensitivity reactions and&nbsp;bronchospasm and <strong>Methyl p-hydroxybenzoate (E 218)</strong>, which may cause allergic reactions (possibly delayed).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Diuretics (thiazides):</u> in elderly patients concurrently receiving diuretics, mainly thiazides, there appears to be an increased risk of thrombocytopenia with or without purpura.</p><p><u>Pyrimethamine:</u> occasional reports suggest that patients receiving pyrimethamine at doses in excess of 25 mg weekly may develop megaloblastic anaemia should trimethoprim-sulfamethoxazole be prescribed concurrently.</p><p><u>Zidovudine:</u> in some situations, concomitant treatment with zidovudine may increase the risk of haematological adverse reactions to trimethoprim-sulfamethoxazole. If concomitant treatment is necessary, consideration should be given to monitoring of haematological parameters.</p><p><u>Lamivudine:</u> administration of trimethoprim/sulfamethoxazole 160 mg/800 mg causes a 40% increase in lamivudine exposure because of the trimethoprim component. Lamivudine has no effect on the pharmacokinetics of trimethoprim or sulfamethoxazole.<br />Warfarin: trimethoprim-sulfamethoxazole has been shown to potentiate the anticoagulant activity of warfarin via stereo-selective inhibition of its metabolism. Sulfamethoxazole may displace warfarin from plasma-albumin protein-binding sites in vitro. Careful control of the anticoagulant therapy during treatment with Septrin is advisable.</p><p><u>Phenytoin:</u> trimethoprim-sulfamethoxazole prolongs the half-life of phenytoin and if co-administered the prescriber should be alert for excessive phenytoin effects. Close monitoring of the patient&#39;s condition and serum phenytoin levels are advisable.<br />Interaction with sulphonylurea hypoglycaemic agents is uncommon but potentiation has been reported.</p><p><u>Rifampicin:</u> concurrent use of rifampicin and Septrin results in a shortening of the plasma half-life of trimethoprim after a period of about one week. This is not thought to be of clinical significance.</p><p><u>Cyclosporin:</u> reversible deterioration in renal function has been observed in patients treated with trimethoprim and sulfamethoxazole and cyclosporin following renal transplantation.</p><p>When trimethoprim is administered simultaneously with drugs that form cations at physiological pH, and are also partly excreted by active renal secretion (e.g. procainamide, amantadine), there is the possibility of competitive inhibition of this process which may lead to an increase in plasma concentration of one or both of the drugs.</p><p><u>Digoxin: </u>concomitant use of trimethoprim with digoxin has been shown to increase plasma digoxin levels in a proportion of elderly patients.</p><p><u>Hyperkalaemia:</u> caution should be exercised in patients taking any other drugs that can cause hyperkalaemia, for example ACE inhibitors, angiotensin receptor blockers and potassium-sparing diuretics such as spironolactone. Concomitant use of trimethoprim-sulfamethoxazole (co-trimoxazole) may result in clinically relevant hyperkalaemia.</p><p><u>Azathioprine:</u> There are conflicting clinical reports of interactions, resulting in serious haematological abnormalities, between azathioprine and trimethoprim-sulfamethoxazole.</p><p><u>Methotrexate:</u> trimethoprim-sulfamethoxazole may increase the free plasma levels of methotrexate. If&nbsp;Septrin is considered appropriate therapy in patients receiving other anti-folate drugs such as methotrexate, a folate supplement should be considered (see section 4.4).</p><p><u>Repaglinide: </u>trimethoprim may increase the exposure of repaglinide which may result in hypoglycaemia.</p><p><u>Folinic acid:</u> folinic acid supplementation has been shown to interfere with the antimicrobial efficacy of trimethoprim-sulfamethoxazole. This has been observed in Pneumocystis jirovecii pneumonia prophylaxis and treatment.</p><p><u>Contraceptives:</u> oral contraceptive failures have been reported with antibiotics. The mechanism of this effect has not been elucidated. Women on treatment with antibiotics should temporarily use a barrier method in addition to the oral contraceptive, or choose another method of contraception.</p><p><u>Interaction with laboratory tests:</u></p><p>Trimethoprim interferes with assays for serum methotrexate when dihydrofolate reductase from Lactobacillus casei is used in the assay. No interference occurs if methotrexate is measured by radio-immune assay.</p><p>Trimethoprim may interfere with the estimation of serum/plasma creatinine when the alkaline picrate reaction is used. This may result in overestimation of serum/plasma creatinine of the order of 10%.<br />Functional inhibition of the renal tubular secretion of creatinine may produce a spurious fall in the estimated rate of creatinine clearance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />Trimethoprim and sulfamethoxazole cross the placenta and their safety in human pregnancy has not been established. Trimethoprim is a folate antagonist and, in animal studies, both agents have been shown to cause foetal abnormalities (see section 5.3). Case-control studies have shown that there may be an association between exposure to folate antagonists and birth defects in humans. Therefore Septrin should be avoided in pregnancy, particularly in the first trimester, unless the potential benefit to the mother outweighs the potential risk to the foetus; folate supplementation should be considered if Septrin is used in pregnancy</p><p>Sulfamethoxazole competes with bilirubin for binding to plasma albumin. As significant maternally derived drug levels persist for several days in the newborn, there may be a risk of precipitating or exacerbating neonatal hyperbilirubinaemia, with an associated theoretical risk of kernicterus, when Septrin is administered to the mother near the time of delivery. This theoretical risk is particularly relevant in infants at increased risk of hyperbilirubinaemia, such as those who are preterm and those with glucose-6- phosphate dehydrogenase deficiency.</p><p><u>Breast Feeding</u><br />Trimethoprim and sulfamethoxazole are excreted in breast milk. Administration of Septrin should be avoided in late pregnancy and in lactating mothers where the mother or infant has, or is at particular risk of developing, hyperbilirubinaemia. Additionally, administration of Septrin should be avoided in infants younger than eight weeks in view of the predisposition of young infants to hyperbilirubinaemia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects on the ability to drive and operate machinery in patients taking this medicine have not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As Septrin contains trimethoprim and a sulphonamide the type and frequency of adverse reactions associated with such compounds are expected to be consistent with extensive historical experience.</p><p>Data from large published clinical trials were used to determine the frequency of very common to rare adverse events. Very rare adverse events were primarily determined from post-marketing experience data and therefore refer to reporting rate rather than a &quot;true&quot; frequency. In addition, adverse events may vary in their incidence depending on the indication.</p><p>The following convention has been used for the classification of adverse events in terms of frequency:</p><p>Very common &ge;1/10,</p><p>Common &ge;1/100 and &lt;1/10,</p><p>Uncommon &ge;1/1000 and &lt;1/100,</p><p>Rare &ge;1/10,000 and &lt;1/1000,</p><p>Very rare &lt;1/10,000</p><p>Not known: cannot be estimated from the available data.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:1546px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top; width:1169px"><p><strong>Side effects</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:1169px"><p>Overgrowth fungal.</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1169px"><p>Leucopenia, neutropenia, thrombocytopenia, agranulocytosis, anaemia megaloblastic, aplastic anaemia, haemolytic anaemia, methaemoglobinaemia, eosinophilia, purpura, haemolysis in certain susceptible G‑6‑PD deficient patients.</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1169px"><p>Serum sickness, anaphylactic reactions, allergic myocarditis, hypersensitivity vasculitis resembling Henoch-Schoenlein purpura, periarteritis nodosa, systemic lupus erythematosus.</p><p>Severe hypersensitivity reactions associated with PJP* including rash, pyrexia, neutropenia, thrombocytopenia, hepatic enzyme increased, rhabdomyolosis, hyperkalaemia, hyponatraemia.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top; width:1169px"><p>Hyperkalaemia.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1169px"><p>Hypoglycaemia, hyponatraemia, decreased appetite, metabolic acidosis.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1169px"><p>Depression, hallucination.</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:1169px"><p>Psychotic disorder.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:1169px"><p>Headache.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1169px"><p>Meningitis aseptic*, seizure, neuropathy peripheral, ataxia, dizziness.</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth&nbsp; disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1169px"><p>Vertigo, tinnitus</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1169px"><p>Uveitis.</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1169px"><p>Cough*, dyspnoea*, lung infiltration.*</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:1169px"><p>Nausea, diarrhoea.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:1169px"><p>Vomiting.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1169px"><p>Glossitis, stomatitis, pseudomembranous colitis, pancreatitis.</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1169px"><p>Jaundice cholestatic *, hepatic necrosis*,</p><p>transaminases increased, blood bilirubin increased.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders*</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:1169px"><p>Rash.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1169px"><p>Photosensitivity reaction, angioedema, dermatitis exfoliative, fixed drug eruption, erythema multiforme, Stevens-Johnson syndrome (SJS)*, toxic epidermal necrolysis (TEN)*.</p></td></tr><tr><td style="vertical-align:top"><p>Not Known</p></td><td style="vertical-align:top; width:1169px"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)*</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1169px"><p>Arthralgia, myalgia.</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1169px"><p>Renal impairment (sometimes reported as renal failure), tubulointerstitial nephritis.</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1169px"><p>Pyrexia.</p></td></tr></tbody></table><p>* see description of selected adverse reactions</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>Aseptic meningitis</em></p><p><em>&nbsp;</em>Aseptic meningitis was rapidly reversible on withdrawal of the drug, but recurred in a number of cases on re‑exposure to either Septrin or to trimethoprim alone.</p><p><em>Pulmonary hypersensitivity reactions</em></p><p><em>&nbsp;</em>Cough, dyspnoea and lung infiltration may be early indicators of respiratory hypersensitivity which, while very rare, has been fatal.</p><p><em>Severe cutaneous adverse reactions (SCARs) </em></p><p><em>&nbsp;</em>Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported to be life-threatening (see section 4.4).</p><p><em>Hepatobiliary disorders </em></p><p>Jaundice cholestatic and hepatic necrosis may be fatal.</p><p><em>Effects associated with Pneumocystis jirovecii (P. carinii) Pneumonitis (PJP) management</em></p><p>At the high dosages used for PJP management severe hypersensitivity reactions have been reported, necessitating cessation of therapy. Severe hypersensitivity reactions have been reported in PJP patients on re‑exposure to trimethoprim-sulfamethoxazole, sometimes after a dosage interval of a few days. Rhabdomyolysis has been reported in HIV positive patients receiving Septrin for prophylaxis or treatment of PJP.</p><p>To reports any side effect(s):</p><p><strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:805px"><tbody><tr><td style="vertical-align:top; width:801px"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:798px"><tbody><tr><td style="vertical-align:top; width:795px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u><br />Nausea, vomiting, dizziness and confusion are likely signs/symptoms of overdose. Bone marrow depression has been reported in acute trimethoprim overdose.</p><p><u>Management</u><br />Dependent on the status of renal function administration of fluids is recommended if urine output is low.</p><p>Both trimethoprim and active sulfamethoxazole are moderately dialysable by haemodialysis.</p><p>Peritoneal dialysis is not effective.</p><p>In cases of known, suspected or accidental overdose, stop therapy.<br />Acidification of the urine will increase the elimination of trimethoprim. Inducing diuresis plus alkalinisation of urine will enhance the elimination of sulfamethoxazole. Alkalinisation will reduce the rate of elimination of trimethoprim. Calcium folinate (5 to 10 mg/day) will reverse any folate deficiency effect of trimethoprim on the bone marrow should this occur. General supportive measures are recommended</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: <strong>ANTIBACTERIALS FOR SYSTEMIC USE &ndash; SULFONAMIDES AND TRIMETHOPRIM</strong> Combinations of sulfonamides and trimethoprim, incl. derivatives; ATC code: J01EE01</p><p><u>Mechanism of action</u><br />Sulfamethoxazole competitively inhibits the utilisation of para-aminobenzoic acid in the synthesis of dihydrofolate by the bacterial cell resulting in bacteriostasis. Trimethoprim reversibly inhibits bacterial dihydrofolate reductase (DHFR), an enzyme active in the folate metabolic pathway converting dihydrofolate to tetrahydrofolate. Depending on the conditions the effect may be bactericidal. Thus trimethoprim and sulfamethoxazole block two consecutive steps in the biosynthesis of purines and therefore nucleic acids essential to many bacteria. This action produces marked potentiation of activity in vitro between the two agents.<br />Trimethoprim binds to plasmodial DHFR but less tightly than to the bacterial enzyme. The affinity of trimethoprim for mammalian DHFR is some 50,000 times less than for the corresponding bacterial enzyme.</p><p><u>Resistance</u><br />In vitro studies have shown that bacterial resistance can develop more slowly with both sulfamethoxazole and trimethoprim in combination that with either sulfamethoxazole or trimethoprim alone.</p><p>Resistance to sulfamethoxazole may occur by different mechanisms. Bacterial mutations cause an&nbsp;increase the concentration of PABA and thereby out-compete with sulfamethoxazole resulting in a reduction of the inhibitory effect on dihydropteroate synthetase enzyme. Another resistance mechanism is plasmid-mediated and results from production of an altered dihydropteroate synthetase enzyme, with reduced affinity for sulfamethoxazole compared to the wild-type enzyme.<br />Resistance to trimethoprim occurs through a plasmid-mediated mutation which results in production of an altered dihydrofolate reductase enzyme having a reduced affinity for trimethoprim compared to the wild-type enzyme.</p><p><u>Susceptibility testing breakpoints</u><br />Testing of trimethoprim - sulfamethoxazole was performed using the common dilution series to assess the Minimum Inhibitory Concentration (MIC). The MIC breakpoints for resistance are those recommended by CLSI (Clinical and Laboratory Standards Institute &ndash; formerly the National Committee for Clinical Laboratory Standards (NCCLS) and EUCAST guidelines.</p><p><u>Pharmacodynamic effects</u><br />The majority of common pathogenic bacteria are sensitive in vitro to trimethoprim and sulfamethoxazole at concentrations well below those reached in blood, tissue fluids and urine after the administration of recommended doses. In common with other antimicrobial agents in vitro activity does not necessarily imply that clinical efficacy had been demonstrated. These organisms include:</p><table border="1" cellspacing="0" cellpadding="0" style="width:826px"><tbody><tr><td style="vertical-align:top; width:823px"><p><strong>Gram Negative</strong></p></td></tr><tr><td style="vertical-align:top; width:823px"><p><em>Brucella spp. </em></p><p><em>Citrobacter spp.</em></p><p><em>Escherichia coli (including ampicillin-resistant strains)</em></p><p><em>Haemophilus ducreyi</em></p><p><em>Haemophilus influenzae (including ampicillin-resistant &nbsp;strains) Klebsiella/Enterobacter spp.</em></p><p><em>Legionella pneumophila</em></p><p><em>Morganella morganii (previously Proteus morganii)</em></p><p><em>Neisseria spp.</em></p><p><em>Proteus spp.</em></p><p><em>Providencia spp. (including previously Proteus rettgeri) </em></p><p><em>Certain Pseudomonas &nbsp;spp. except aeruginosa </em></p><p><em>Salmonella </em><em>spp. including </em>S. <em>typhi and paratyphi. </em></p><p><em>Serratia marcescens.</em></p><p><em>Shingella spp. </em></p><p><em>Vibrio cholerae </em></p><p><em>Yersinia spp.</em></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:823px"><p><strong>Gram positive</strong></p></td></tr><tr><td style="vertical-align:top; width:823px"><p><em>Listeria monocytogenes.</em></p><p><em>Nocardia spp. </em></p><p><em>Staohylococcus aureus.</em></p><p><em>Staphylococcus epidermidis and saprophyticus</em></p><p><em>Enterococcus faecalis. </em></p><p><em>Streptococcus pneumoni ae. </em></p><p><em>Streptococcus viridans.</em></p><p>&nbsp;</p></td></tr></tbody></table><p>Many strains of Bacteroides fragilis are sensitive. Some strains of Campylobacter fetus subsp. Jejuni and chlamydia are sensitive without evidence of synergy. Some varieties of non-tuberculous mycobacteria are sensitive to sulfamethoxazole but not trimethoprim. Mycoplasmas, Ureaplasma urealyticum, Mycobacterium tuberculosis and Treponema pallidum are insensitive.</p><p>Satisfactory sensitivity testing is achieved only with recommended media free from inhibitory substances especially thymidine and thymine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption:</u><br />After oral administration trimethoprim - sulfamethoxazole are rapidly and nearly completely absorbed. The presence of food does not appear to delay absorption. Peak levels in the blood occur between one and four hours after ingestion and the level attained is dose related. Effective levels persist in the blood for up to 24 hours after a therapeutic dose. Steady state levels in adults are reached after dosing for 2-3 days. Neither component has an appreciable effect on the concentrations achieved in the blood by the other.</p><p><u>Distribution:</u><br />Approximately 50% of trimethoprim in the plasma is protein bound. Tissue levels of trimethoprim are generally higher than corresponding plasma levels, the lungs and kidneys showing especially high concentrations. Trimethoprim concentrations exceed those in plasma in the case of bile, prostatic fluid and tissue, saliva, sputum and vaginal secretions. Levels in the aqueous humor, breast milk, cerebrospinal fluid, middle ear fluid, synovial fluid and tissue (interstitial) fluid are adequate for antibacterial activity. Trimethoprim passes into amniotic fluid and foetal tissues reaching concentrations approximating those of maternal serum. Approximately 66% of sulfamethoxazole in the plasma is protein bound. The concentration of active sulfamethoxazole in amniotic fluid, aqueous humour, bile, cerebrospinal fluid, middle ear fluid, sputum, synovial fluid and tissue (interstitial) fluid is of the order of 20-50% of the plasma concentration.</p><p><u>Biotransformation:</u><br />Renal excretion of intact sulfamethoxazole accounts for 15-30% of the dose. This drug is more extensively metabolised than trimethoprim, via acetylation, oxidation or glucuronidation. Over a 72-hour period, approximately 85% of the dose can be accounted for in the urine as unchanged drug plus the major (N4-acetylated) metabolite.</p><p><u>Elimination:</u><br />The half-life of trimethoprim in man is in the range 8.6 to 17 hours in the presence of normal renal function. There appears to be no significant difference in the elderly compared with young patients.</p><p>The principal route of excretion of trimethoprim is renal and approximately 50% of the dose is excreted in the urine within 24 hours as unchanged drug. Several metabolites have been identified in the urine. Urinary concentration of trimethoprim varies widely.</p><p>The half-life of sulfamethoxazole in man is approximately 9-11 hours in the presence of normal renal function. There is no change in the half-life of active sulfamethoxazole with a reduction in renal function but there is prolongation of the half-life of the major, acetylated metabolite when the creatinine clearance is below 25 ml/minute.</p><p>The principle route of excretion of sulfamethoxazole is renal; between 15% and 30% of the dose recovered in the urine is in the active form.</p><p><strong>Special patient populations</strong></p><p><strong>Renal impairment</strong></p><p>The elimination half-life of trimethoprim is increased by a factor of 1.5-3.0 when the creatinine clearance is less than 10 mL/minute. When the creatinine clearance falls below 30 mL/min the dosage of Septrin should be reduced (see section 4.2).</p><p><strong>Hepatic impairment</strong></p><p>Caution should be exercised when treating patients with severe hepatic impairment as there may be changes in the absorption and biotransformation of trimethoprim and sulfamethoxazole.</p><p><strong>Older patients</strong></p><p>In older patients, a slight reduction in renal clearance of sulfamethoxazole but not trimethoprim has been observed.</p><p><strong>Paediatric population</strong></p><p>The pharmacokinetics in the paediatric population with normal renal function of both components of Septrin, trimethoprim and sulfamethoxazole are age dependent. Elimination of trimethoprim - sulfamethoxazole is reduced in neonates, during the first two months of life, thereafter both trimethoprim and sulfamethoxazole show a higher elimination with a higher body clearance and a shorter elimination half-life. The differences are most prominent in young infants (&gt; 1.7 months up to 24 months) and decrease with increasing age, as compared to young children (1 year up to 3.6 years), children (7.5 years and &lt; 10 years) and adults (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>At doses in excess of the recommended human therapeutic dose, trimethoprim and sulfamethoxazole have been reported to cause cleft palate and other foetal abnormalities in rats, findings typical of a folate antagonist. Effects with trimethoprim were preventable by co-administration of dietary folate. In rabbits, foetal loss was seen at doses of trimethoprim in excess of human therapeutic doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sorbitol solution 70% E420<br />Glycerol<br />Dispersible cellulose<br />Carmellose sodium<br />Polysorbate 80<br />Methyl hydroxybenzoate E218<br />Sodium Benzoate E211<br />Saccharin Sodium<br />Ethanol<br />Banana Flavour<br />Vanilla flavour containing sulphur dioxide E220<br />Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C.<br />Keep the bottle in the outer carton in order to protect from light.<br />Once opened: use within 6 weeks</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type III amber glass bottles closed with polypropylene child resistant closures fitted with an EPE/Saranex liner</p><p>Or</p><p>Type III amber glass bottles closed with metal roll-on pilfer proof (ROPP) caps fitted with polyvinylidene chloride (PVDC) faced wads.<br />Bottles of 50 and 100 ml.<br />This pack contains a polypropylene double-ended 5 ml/2.5 ml spoon.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Septrin Paediatric Suspension may be diluted with Syrup BP. Although they may show some sedimentation such dilutions remain stable for at least a month. Shake thoroughly before use.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen Pharma Trading Limited
3016 Lake Drive,
Citywest Business Campus,
Dublin 24,
Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>